menu
    • menu

    Company profile for ERS Genomics

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    ERS Genomics was formed to commercialise the foundational CRISPR-Cas9 intellectual property held by co-inventor, co-owner and Nobel Prize-winner Dr. Emmanuelle Charpentier. Licenses are available in multiple fields of use. CRISPR-Cas9 is a revolutionary new genome editing technology, which offers significant advantages in speed, efficiency and cost over earlier genome editing methods. Our team has decades of experience in ...
    ERS Genomics was formed to commercialise the foundational CRISPR-Cas9 intellectual property held by co-inventor, co-owner and Nobel Prize-winner Dr. Emmanuelle Charpentier. Licenses are available in multiple fields of use. CRISPR-Cas9 is a revolutionary new genome editing technology, which offers significant advantages in speed, efficiency and cost over earlier genome editing methods. Our team has decades of experience in the field of genome editing and its application, in business development and licensing, licensing preclinical and clinical stage therapeutic products and drug delivery technologies, genome editing technologies.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    ERS GenomicsIreland Flag
    Country
    Country
    Ireland
    Address
    Address
    8th Floor, Block E, Iveagh Court, Harcourt Road, Dublin D02 YT22, Ireland
    Telephone
    Telephone
    +353 (0)1 539-0082
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://ersgenomics.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/ers-genomics/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/ersgenomics

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Natural Product Expo West

    Natural Product Expo West

    Not Confirmed

    envelop Contact Supplier

    Natural Product Expo West

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    ERS Genomics Launches New Early Access Express License
    ERS Genomics Launches New Early Access Express License

    24 Feb 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ers-genomics-launches-new-early-access-express-license-302695596.html

    PR NEWSWIRE
    24 Feb 2026
    Share Share
    ERS Genomics, Dyadic Biosolutions Ink CRISPR/Cas9 License Deal
    ERS Genomics, Dyadic Biosolutions Ink CRISPR/Cas9 License Deal

    10 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ers-genomics-and-dyadic-applied-biosolutions-sign-crisprcas9-license-agreement-302610320.html

    PR NEWSWIRE
    10 Nov 2025
    Share Share
    ERS Genomics Launches ‘Express License’ For CRISPR/Cas9 Access
    ERS Genomics Launches ‘Express License’ For CRISPR/Cas9 Access

    13 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/13/3008603/0/en/ERS-Genomics-launches-Express-License-platform-to-democratise-access-to-CRISPR-Cas9.html

    GLOBENEWSWIRE
    13 Jan 2025
    Share Share
    ERS Genomics and Medicines Discovery Catapult Sign CRISPR/Cas9 License Agreement
    ERS Genomics and Medicines Discovery Catapult Sign CRISPR/Cas9 License Agreement

    04 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240904321742/en

    BUSINESSWIRE
    04 Sep 2024
    Share Share
    ERS Genomics and IRBM Sign CRISPR/Cas9 License Agreement
    ERS Genomics and IRBM Sign CRISPR/Cas9 License Agreement

    20 May 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240520044085/en

    BUSINESSWIRE
    20 May 2024
    Share Share
    ERS Genomics Appoints John E Milad as Chief Executive Officer
    ERS Genomics Appoints John E Milad as Chief Executive Officer

    13 May 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240513334659/en

    BUSINESSWIRE
    13 May 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search